Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors: Traina, F  Visconte, V  Elson, P  Tabarroki, A  Jankowska, AM  Hasrouni, E  Sugimoto, Y  Szpurka, H  Makishima, H  O'Keefe, CL  Sekeres, MA  Advani, AS  Kalaycio, M  Copelan, EA  Saunthararajah, Y  Olalla Saad, ST  Maciejewski, JP  Tiu, RV 
Citation: Traina F, etal., Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18.
Pubmed: (View Article at PubMed) PMID:24045501
DOI: Full-text: DOI:10.1038/leu.2013.269

We hypothesized that specific molecular mutations are important biomarkers for response to DNA methyltransferase inhibitors (DNMT inhibitors) and may have prognostic value in patients with myelodysplastic syndromes (MDS). Mutational analysis was performed in 92 patients with MDS and related disorders who received 5-azacytidine (n=55), decitabine (n=26) or both (n=11). Mutational status was correlated with overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) by univariate and multivariate analysis. Risk stratification models were created. TET2, DNMT3A, IDH1/IDH2, ASXL1, CBL, RAS and SF3B1 mutations were found in 18, 9, 8, 26, 3, 2 and 13% of patients, respectively. In multivariate analysis, TET2(MUT) and/or DNMT3A(MUT) (P=0.03), platelets > or = 100 x 10(9)/l (P=0.007) and WBC<3.0 x 10(9)/l (P=0.03) were independent predictors of better response. TET2(MUT) and/or DNMT3A(MUT) (P=0.04) status was also independently prognostic for improved PFS, as were good or intermediate cytogenetic risk (P<0.0001), age<60 (P=0.0001), treatment with both 5-azacytidine and decitabine (P=0.02) and hemoglobin > or = 10 g/dl (P=0.01). Better OS was associated with ASXL1(WT) (P=0.008) and SF3B1(MUT) (P=0.01), and, similar to PFS, cytogenetic risk (P=0.0002), age (P=0.02) and hemoglobin (P=0.04). These data support the role of molecular mutations as predictive biomarkers for response and survival in MDS patients treated with DNMT inhibitors.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11038769
Created: 2016-02-24
Species: All species
Last Modified: 2016-02-24
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.